Bone Therapeutics Launches Phase IIA Study for Treatment of Multiple Fractures with ALLOB

Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.

The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us